Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Total 13F shares
-
28,180,241
-
Share change
-
+4,492,111
-
Total reported value
-
$136,388,000
-
Put/Call ratio
-
41%
-
Price per share
-
$4.84
-
Number of holders
-
55
-
Value change
-
+$22,907,893
-
Number of buys
-
30
-
Number of sells
-
26
Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q3 2021
As of 30 Sep 2021,
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,180,241 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, TANG CAPITAL MANAGEMENT LLC, VR Adviser, LLC, ADAMS STREET PARTNERS LLC, EcoR1 Capital, LLC, BVF INC/IL, VANGUARD GROUP INC, Ikarian Capital, LLC, PURA VIDA INVESTMENTS, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
55
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.